CD11a Antibody [M17/4]

Product Specifications

Background

The M17/4 monoclonal antibody specifically reacts with mouse CD11a, a 180kDA glycoprotein. CD11a is the integrin alpha L chain that forms with CD18 the heterodimer molecule Lymphocyte Function-associated Antigen-1 (LFA-1) . LFA-1 is expressed on all leukocytes and is involved in intercellular adhesions. The M17/4 antibody blocks many of the LFA-1 mediated cell interaction and in vivo it prolongs allograft survival, inhibits the autoimmune response, and reduces graft versus host reactions.

NCBI Gene ID

16408

Swiss Prot

P24063

Host

Rat

Reactivity

Mouse

Clonality

Monoclonal

Clone

M17/4

Conjugation

Unconjugated

Type

Primary Antibodies, Functional Antibodies

Field of Research

Cancer

Purification

The monoclonal antibody was purified utilizing affinity chromatography. The endotoxin level is determined by LAL test to be less than 0.01 EU/µg of the protein.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C . Do not freeze.

Fragment

Rat IgG2a, kappa

Specificity

The M17/4 monoclonal antibody specifically reacts with mouse CD11a, a 180kDA glycoprotein.

Symbol

Itgal

NCBI Official Name

Integrin alpha L

NCBI Organism

Mus musculus

Background Reference 01

Saban, M. R., Saban, R., Bjorling, D., Haak-Frendscho, M. (1997) . Involvement of leukotrienes, TNF-alpha, and the LFA-1/ICAM-1 interaction in substance P-induced granulocyte infiltration.Journal of leukocyte biology,61 (4), 445-451.

Background Reference 02

Zhao, Y., Iwata, M. (1995) . Cross-linking of the TCRCD3 complex with CD4, CD8 or LFA-1 induces an anti-apoptotic signal in thymocytes: the signal is canceled by FK506.International immunology,7 (9), 1387-1396.

Background Reference 03

Kootstra, C. J., Van Der Giezen, D. M., Van Krieken, J. H. J. M., De Heer, E., Bruijn, J. A. (1997) . Effective treatment of experimental lupus nephritis by combined administration of anti‐CD11a and anti‐CD54 antibodies.Clinical Experimental Immunology,108 (2), 324-332.